For Immediate Release
Chicago, IL – June 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Visa (V - Free Report) , Medtronic (MDT - Free Report) , Salesforce CRM, Dollar General (DG - Free Report) and Martin Marietta (MLM - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Visa, Medtronic and Salesforce
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa, Medtronic and Salesforce. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the last year (+35.5% vs. +32.9%). The company is witnessing growth in payments volume, cross-border volume and processed transactions as a strong economy and a positive consumer sentiment drives higher spending.
Numerous strategic acquisitions and alliances, technology upgrades and effective marketing have paved the way for its long-term growth and consistent revenue improvement. The Zacks analyst thinks Visa is well poised to gain from the growing electronic payment processing and strong international business. A solid balance sheet ensures effective capital deployment.
The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 2% upward over the last 60 days. Nevertheless, high client incentives might put pressure on revenues.
(You can read the full research report on Visa here >>>).
Shares of Medtronic have outperformed the Zacks Medical Products industry in the last three months, gaining +10.1% vs. +6.1%. Medtronic exited the fiscal 2018 on a solid note with better-than-expected fourth quarter performances. All major business groups contributed to solid top-line growth at CER, highlighting sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets.
The Zacks analyst thinks the gradually stabilizing CRHF market holds promise. The receipt of FDA approval for the DBS therapy as adjunctive treatment to reduce partial-onset seizures buoys optimism. The company is also focusing on geographical diversification of its businesses. Medtronic is highly positive about its foray into the $1 billion standalone CGM market with its Guardian Connect.
However, escalating costs and expenses continue to weigh on the bottom line. The company’s 2019 guidance remains conservative on apprehension of lackluster CVG and MITG performances.
(You can read the full research report on Medtronic here >>>).
Salesforce’s shares have handily beaten the broader Tech sector over the last year, with the stock up nearly three time the Zacks Technology sector's +15.4% gain. Salesforce reported stellar first-quarter fiscal 2019 results on the back of rapid adoption of the company’s cloud-based solutions.
The Zacks analyst thinks enhancement of customer experience via artificial intelligence related innovations have further aided the growth. Additionally, strategic acquisitions and the resultant synergies are anticipated to prove conducive to growth over the long run.
Furthermore, the company is on track to reach its $20 billion annual revenue mark. Nonetheless, stiff competition and an increase in investments for international expansions and data centers could negatively impact near-term profitability.
(You can read the full research report on Salesforce here >>>).
Other noteworthy reports we are featuring today include Dollar General and Martin Marietta.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.